A financial voice that leaves clinical authority intact
My contribution to a board
I would bring a financial view of services whose dependable delivery requires work that is not separately billable. A board may see a cost-per-report measure without understanding the controls, support and transition activity beneath it. I can help directors ask whether the financial model preserves those obligations and whether a proposed commercial improvement changes them. My experience includes comparing supplier commitments, interpreting customer-service costs and funding equipment transitions. It does not make me a clinician or a laboratory-quality authority. I have presented recommendations to directors but have not held a seat myself. A first appointment should therefore have a defined contribution and an experienced chair who expects me to learn the company's responsibilities. I would be interested in audit and investment discussions where financial scrutiny complements professional expertise, with a clear route for the board to hear directly from the people accountable for the technical or clinical work.
Judgement in practice
01
Examining the purchase obligation behind an attractive unit price
The reagent renewal required us to look beyond the lowest stated price and ask which consumption assumptions made the minimum commitment supportable. On another board, I would ask how management had established that range and whether the comparison included the service and exit conditions that mattered. I would want the qualified professional team to identify acceptable options before finance ranked their economics. The higher unit price we accepted was a real disadvantage at greater activity, and the initial fee reduced the first-year benefit. A board should be able to see those consequences without needing to reconstruct the contract itself. The purpose of challenge is not to make every commitment smaller, but to ensure that the company understands the circumstances under which its preferred option is useful and when the decision should be reconsidered.
02
Treating transition cost as part of the investment decision
The instrument replacement showed why a supported operating transition may require expenditure that looks duplicated in an annual budget. I would ask another board whether the investment paper distinguishes installation from readiness to carry the intended service. Management should explain the conditions, responsible professional and funding allowance for that stage. I would also expect a review point, so that the overlap does not become an indefinite arrangement without a fresh decision. The financial director should neither force a premature transition to protect a forecast nor accept an unexplained extension because the project has already been approved. I would help the board keep the original investment purpose, the current evidence and the remaining commitment visible together, while respecting the authority of those qualified to determine clinical or technical readiness.
My first year on a board
My first priority would be to understand where professional judgement sits within the organisation and how its consequences reach the board. I would ask the chair to arrange introductions to the relevant clinical or technical leaders, alongside finance, commercial and operations colleagues. A small number of supplier and customer examples would help me learn the service model more effectively than a large general presentation. During the first reporting cycle, I would examine how management explains material differences between purchased activity, delivered service and billable output. I would also review the conditions attached to major investments and how the board follows them after approval. I would not assume that the reporting format used in my current company is the right answer elsewhere. My early contribution should improve the questions directors ask while allowing the management team to retain its work. I would seek the chair's feedback on where my financial perspective is useful and where I need more grounding in the new company's professional obligations.
Conflicts and their management
Our group works with hospitals, clinics, equipment and reagent suppliers, service providers and a minority financial investor. A prospective board role could connect with those relationships even if its principal service differs from ours. I would disclose my employment and relevant interests, discuss consent with my employer and review the proposed company's connections with its chair and advisers. I would not share customer pricing, procurement terms or confidential professional information between organisations. Where a recurring matter would require me to withdraw from the discussion, I would assess whether the seat could still receive the contribution expected. Time also needs a practical review. Twenty-two days is an opening allowance that must cover preparation and committee work as well as meetings, alongside my current reporting responsibilities. I would reconsider the commitment if a major transaction or operational change altered those demands. An external appointment should be feasible in the circumstances that actually arise, not only under the most convenient annual calendar.
My independence statement
My current employment and relationships through customers, suppliers and investors require review before any external independence assessment. I would not infer independence from a different company name or an unpaid appointment.
Board and committee exposure
Presented to the Board or a committee
Luyanshu Diagnostic Services
Board reporting and investment discussions
August 2020–present
Presents group financial results, supplier commitments and investment recommendations as CFO; no director appointment.
Governance learning and readiness
IICA Independent Directors’ Databank: Not yet registered
My present board interest concerns Chinese service companies; I have no registration in the Indian independent-director databank.
I am reviewing how directors distinguish financial oversight from interference in professional decision-making.
My preparation includes discussion of board papers with experienced colleagues and study of how investment conditions are followed after approval.